Supplementary

Table S1 Clinical and pathological characteristics in patients with GGO and solid nodules

| Variables | All ( $\mathrm{n}=5,200$ ) | GGO ( $\mathrm{n}=1,609$ ) | Solid nodules ( $\mathrm{n}=3,591$ ) | $P$ value |
| :---: | :---: | :---: | :---: | :---: |
| Sex |  |  |  | <0.001 |
| Male | 2,885 (55.5) | 611 (38.0) | 2,274 (63.3) |  |
| Female | 2,315 (44.5) | 998 (62.0) | 1,317 (36.7) |  |
| Age |  |  |  | <0.001 |
| <60 years | 2,478 (47.7) | 809 (50.3) | 1,669 (46.5) |  |
| $\geq 60$ years | 2,722 (52.3) | 800 (49.7) | 1,922 (53.5) |  |
| Smoking |  |  |  | <0.001 |
| Never | 3,204 (61.6) | 1,281 (79.6) | 1,923 (53.6) |  |
| Former/current | 1,996 (38.4) | 328 (20.4) | 1,668 (46.4) |  |
| Pathology types |  |  |  | <0.001 |
| IAC | 3,932 (75.6) | 1,543 (95.9) | 2,389 (66.5) |  |
| SCC | 1,223 (23.5) | 56 (3.5) | 1,167 (32.5) |  |
| Others | 45 (0.9) | 10 (0.6) | 35 (1.0) |  |
| pT stage |  |  |  | <0.001 |
| 1a | 377 (7.3) | 222 (13.8) | 155 (4.3) |  |
| 1 b | 1,637 (31.5) | 841 (52.3) | 795 (22.1) |  |
| 1 c | 1,147 (22.1) | 274 (17.0) | 872 (24.3) |  |
| 2 a | 1,052 (20.2) | 161 (10.0) | 891 (24.8) |  |
| 2 b | 379 (7.3) | 30 (1.9) | 349 (9.7) |  |
| 3 | 366 (7.0) | 39 (2.4) | 327 (9.1) |  |
| 4 | 242 (4.7) | 41 (2.5) | 201 (5.6) |  |
| pN stage |  |  |  | <0.001 |
| 0 | 3,639 (70.0) | 1,463 (90.9) | 2,176 (60.6) |  |
| 1 | 487 (9.4) | 52 (3.2) | 435 (12.1) |  |
| 2 | 1,066 (20.5) | 93 (5.8) | 93 (2.6) |  |
| 3 | 8 (0.2) | 1 (0.1) | 7 (0.2) |  |
| Number of LN resected | $18.0 \pm 32.3$ | $14.7 \pm 26.5$ | $19.5 \pm 34.5$ | <0.001 |
| PTNM stage |  |  |  | <0.001 |
| Stage I | 3,127 (60.1) | 1,379 (85.7) | 1,748 (48.7) |  |
| Stage II | 769 (14.8) | 96 (6.0) | 673 (18.7) |  |
| Stage III | 1,304 (25.1) | 134 (8.3) | 134 (3.7) |  |
| $R$ descriptors |  |  |  | <0.001 |
| RO | 3,228 (62.1) | 1,052 (65.4) | 2,176 (60.6) |  |
| R(un) | 1,727 (33.2) | 531 (33.0) | 1,196 (33.3) |  |
| R1 | 151 (2.9) | 17 (1.1) | 134 (3.7) |  |
| R2 | 94 (1.8) | 9 (0.6) | 85 (2.4) |  |

GGO, ground-glass opacity; IAC, invasive adenocarcinoma; SCC, squamous cell carcinoma; pT, pathological tumor; pN pathological node; LN, lymph node; pTNM, pathological tumor-node-metastasis.


Figure S1 OS and RFS of UICC R descriptors: (A) comparisons of OS between UICC R0, R1, and R2; (B) comparisons of RFS between UICC R0, R1, and R2. The $95 \%$ CIs are shown as shaded areas. UICC, Union for International Cancer Control; OS, overall survival; RFS, recurrence-free survival; CI, confidential interval.

Table S2 Reasons for recategorization

| $\mathrm{RO} \rightarrow \mathrm{R}(\mathrm{un})$ | Value $(\mathrm{n}=1,727)$ |
| :--- | :---: |
| Summary | $1,179(68.3)$ |
| Rigorous LSND/SND not performed | $663(38.3)$ |
| The highest LN resected (+) | $3(0.2)$ |
| CIS at margin |  |
| Details | $1,061(61.4)$ |
| Rigorous LSND/SND not performed only | $546(31.6)$ |
| The highest LN resected (+) only | $2(0.1)$ |
| CIS at margin only | $117(6.8)$ |
| Rigorous LSND/SND not performed \& highest LN resected (+) | $1(0.1)$ |
| Rigorous LSND/SND not performed \& CIS at margin |  |

Values are presented as n (\%). R(un), uncertain resection; LSND, lobe-specific nodal dissection; SND, systematic nodal dissection; LN, lymph node; CIS, carcinoma in situ.

Table S3 Details of LSND/SND

| Not performing rigorous LSND/SND | Value $(\mathrm{n}=1,179)$ |
| :--- | :---: |
| N1 samples $<3$ \& N2 samples $<3$ | $592(50.2)$ |
| Site-specific LNs not dissected | $293(24.9)$ |
| Neither standard met | $294(24.9)$ |

[^0]Table S4 Univariable and multivariable analysis of OS

| Variables | Univariable |  |  | Multivariable |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | HR | 95\% CI | P | HR | 95\% CI | P |
| Gender (female vs. male) | 0.564 | 0.494-0.643 | <0.001 | 0.743 | 0.622-0.887 | 0.001 |
| Age ( $\geq 60$ vs. $<60$ years) | 1.428 | 1.260-1.618 | <0.001 | 1.424 | 1.256-1.615 | <0.001 |
| Smoking history (current/former vs. never) | 1.749 | 1.546-1.978 | <0.001 | 1.031 | 0.875-1.215 | 0.717 |
| CT appearance (solid nodules vs. GGO) | 3.873 | 3.167-4.737 | <0.001 | 2.182 | 1.761-2.705 | <0.001 |
| Pathological types |  |  |  |  |  |  |
| SCC vs. IAC | 1.813 | 1.594-2.064 | <0.001 | 0.981 | 0.845-1.138 | 0.801 |
| Others vs. IAC | 1.940 | 1.039-3.624 | 0.038 | 1.085 | 0.579-2.032 | 0.799 |
| pTNM stage (stage II/III vs. stage I) | 4.195 | 3.668-4.798 | <0.001 | 2.954 | 2.554-3.417 | <0.001 |
| Proposed R descriptors |  |  |  |  |  |  |
| R (un) vs. R0 | 1.661 | 1.456-1.895 | <0.001 | 1.400 | 1.223-1.603 | <0.001 |
| R1 vs. R0 | 4.123 | 3.209-5.297 | <0.001 | 2.608 | 2.019-3.368 | <0.001 |
| R2 vs. R0 | 5.164 | 3.849-6.929 | <0.001 | 3.483 | 2.587-4.690 | <0.001 |

OS, overall survival; HR, hazard ratio; CI, confidence interval; CT, computed tomography; GGO, ground-glass opacity; SCC, squamous cell carcinoma; IAC, invasive adenocarcinoma; pTNM, pathological tumor-node-metastasis; R(un), uncertain resection.

Table S5 Univariable and multivariable analysis of RFS

| Variables | Univariable |  |  | Multivariable |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | HR | 95\% CI | P | HR | 95\% CI | P |
| Gender (female vs. male) | 0.658 | 0.592-0.730 | <0.001 | 0.801 | 0.695-0.923 | 0.002 |
| Age ( $\geq 60$ vs. $<60$ years) | 1.166 | 1.054-1.290 | 0.003 | 1.139 | 1.029-1.260 | 0.012 |
| Smoking history (current/former vs. never) | 1.570 | 1.419-1.736 | <0.001 | 1.030 | 0.899-1.180 | 0.668 |
| CT appearance (solid nodules vs. GGO) | 3.384 | 2.917-3.927 | <0.001 | 2.263 | 1.930-2.654 | <0.001 |
| Pathological types |  |  |  |  |  |  |
| SCC vs. IAC | 1.420 | 1.272-1.586 | <0.001 | 0.758 | 0.667-0.862 | <0.001 |
| Others vs. IAC | 1.287 | 0.728-2.273 | 0.385 | 0.681 | 0.384-1.206 | 0.188 |
| pTNM stage (stage II/III vs. stage I) | 3.597 | 3.238-3.995 | <0.001 | 2.690 | 2.398-3.019 | <0.001 |
| Proposed R descriptors |  |  |  |  |  |  |
| R(un) vs. RO | 1.538 | 1.382-1.712 | <0.001 | 1.285 | 1.151-1.434 | <0.001 |
| R1 vs. R0 | 3.229 | 2.587-4.030 | <0.001 | 2.158 | 1.720-2.707 | <0.001 |
| R2 vs. R0 | 4.151 | 3.178-5.422 | <0.001 | 2.647 | 2.021-3.468 | <0.001 |

RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; CT, computed tomography; GGO, ground-glass opacity; SCC, squamous cell carcinoma; IAC, invasive adenocarcinoma; PTNM, pathological tumor-node-metastasis; R(un), uncertain resection.

Table S6 The recurrence pattern between R $0, \mathrm{R}(\mathrm{un}), \mathrm{R} 1$, and R2 groups

| Variables | All $(\mathrm{n}=5,200)$ | $\mathrm{RO}(\mathrm{n}=3,228)$ | $\mathrm{R}(\mathrm{un})(\mathrm{n}=1,727)$ | $\mathrm{R} 1(\mathrm{n}=151)$ | $\mathrm{R} 2(\mathrm{n}=94)$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Any sites | 1,123 | 595 | 446 | 48 | 34 |
| Thorax | 606 | 344 | 216 | 28 | 18 |
| Neck | 44 | 20 | 22 | 1 | 1 |
| Abdomen | 71 | 35 | 27 | 6 | 3 |
| Bone | 204 | 90 | 97 | 9 | 8 |
| Brain | 198 | 106 | 84 | 4 | 4 |

$R(u n)$, uncertain resection.


Figure S2 Comparisons of survival in patients with GGO. (A) OS; (B) RFS. The 95\% CIs are shown as shaded areas. R(un), uncertain resection; GGO, ground-glass opacity; R(un), uncertain resection; OS, overall survival; RFS, recurrence-free survival; CI, confidential interval.


Figure S3 Comparisons of survival in patients with TNM stage I. (A) OS; (B) RFS. The $95 \%$ CIs are shown as shaded areas. R(un), uncertain resection; TNM, tumor-node-metastasis; OS, overall survival; RFS, recurrence-free survival; CI, confidential interval.


Figure S4 Comparisons of survival in radiographic solid adenocarcinoma patients with TNM stage I and with TNM stage II/III. The $95 \%$ CIs are shown as shaded areas. R(un), uncertain resection; TNM, tumor-node-metastasis; CI, confidential interval.

Table S7 HR, $95 \%$ CI, and P value of performing rigorous LSND/SND on multivariable analysis in different subgroups

|  |  | Multivariable analysis of OS |  |
| :--- | :---: | :---: | :---: |
| Different subgroups | HR | $95 \% \mathrm{Cl}$ | P |
| CT appearance |  |  |  |
| GGO | NR | NR | NR |
| Solid | NR | NR | NR |
| Pathology types | 1.138 | $0.941-1.376$ | 0.182 |
| IAC | 1.290 | $1.014-1.641$ | 0.038 |
| SCC |  | NO | NO |
| PTNM stage | NO | $1.098-1.571$ | 0.003 |
| I | 1.314 |  |  |
| II/III |  |  |  |

NR means not reaching the criteria of $P$ value $<0.1$ in univariable analysis; N0 means highest LN resected (-). HR, hazard ratio; CI, confidence interval; LSND, lobe-specific systematic nodal dissection; SND, systematic nodal dissection; OS, overall survival; CT, chest tomography; GGO, ground-glass opacity; IAC, invasive adenocarcinoma; SCC, squamous cell carcinoma; pTNM, pathological tumor-node-metastasis; LN, lymph node.

Table S8 HR, $95 \%$ CI, and P value of highest LN resected (+) on multivariable analysis in different subgroups

|  |  | Multivariable analysis of OS |  |
| :--- | :---: | :---: | :---: |
| Different subgroups | HR | $95 \% \mathrm{Cl}$ | P |
| CT appearance |  |  |  |
| GGO | 2.182 | $1.248-3.817$ | 0.006 |
| Solid | 1.689 | $1.441-1.980$ | $<0.001$ |
| Pathology types | 1.138 | $1.354-1.981$ | $<0.001$ |
| IAC | 1.679 | $1.286-2.192$ | $<0.001$ |
| SCC |  |  | NR |
| PTNM stage | NR | $1.419-1.918$ | $<0.001$ |
| I | 1.650 |  | NR |
| II/III |  |  |  |

NR means not reaching the criteria of $P$ value $<0.1$ in univariable analysis. HR, hazard ratio; CI, confidence interval; LN, lymph node; OS, overall survival; CT, computed tomography; GGO, ground-glass opacity; IAC, invasive adenocarcinoma; SCC, squamous cell carcinoma; pTNM, pathological tumor-node-metastasis.


[^0]:    Values are presented as $\mathrm{n}(\%)$. LSND, lobe-specific nodal dissection; SND, systematic nodal dissection; LN, lymph node.

